samedan logo
 
 
spacer
home > ict > autumn 2017 > a new horizon
PUBLICATIONS
International Clinical Trials

A New Horizon

The British government’s White Paper 'Healthy Lives, Healthy People’, published in 2010, was the first public health strategy to give equal weight to mental and physical health (1). Subsequently, ‘No Health Without Mental Health’, published in 2011, specified its aim to mainstream mental health in England, delivering parity of esteem for mental and physical health services (2). Furthermore, for the first time, in 2013, the Chief Medical Officer chose mental health as the subject of their annual report ‘Public Mental Health Priorities; Investing in the Evidence’ (3). These important policy documents set the scene for a growing conversation and shone a spotlight on the stark truth about the UK’s mental health in the 21st century.

We could no longer hide from the appalling reality that mental ill health represented a staggering 28% of the national disease burden and was the leading cause of sickness absence at work, costing the UK upwards of £105 billion a year, with treatment costs expected to increase by at least 50% over the next 20 years (4). The National Institute for Health and Care Excellence (NICE) also emphasised that common mental health disorders affected a significant proportion of the population (15%) at any one time with potentially long-lasting effects (5). Mental health had long been a Cinderella speciality within medicine, but such figures meant it could not be ignored anymore: policy and investment in the English NHS service needed to be aligned to address the ever-widening gap between physical and mental health.

Alongside increasing recognition and awareness from the government, the general public’s perception of mental ill health was also beginning to change. The depth of associated stigma remains a significant challenge, but the general public’s attitude towards psychological difficulties, especially young people, has noticeably improved as individuals recognise that many people they know are affected by poor mental health. High profile campaigns meant it was becoming easier to talk about mental health and its impact. Conversations online, on buses, in cafés and in homes were occurring, and important steps toward change followed as the NHS in England established the Mental Health Taskforce, which launched its ‘Five Year Forward View for Mental Health’ in February 2016 (6). The Taskforce will report in autumn 2017, setting out key recommendations to tackle mental and physical health inequalities, including its specified priorities for a seven-day crisis response, part of the seven-day NHS service; integrated mental and physical healthcare approaches; promotion and prevention initiatives; and a focus on how research and innovation must drive this change.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Kathryn Abel is National Specialty Lead for Mental Health at the NIHR Clinical Research Network (CRN). She is Professor of Psychological Medicine and Director of the Centre for Women's Mental Health at the University of Manchester, UK and an Honorar Consultant Psychiatrist at Greater Mancester Mental Health NHS Foundation Trust. Kathryn is an internationally acclaimed academic and the current holder of a prestigious European Research Council mid-career award and NIHR Senior Investigator award. Kathryn’s posts include Research Director, Senior Mentor, NICE Appraisal Committee member, Local Division 4 Lead for NIHR CRN and Royal College of Psychiatrists Academic Faculty member.
spacer
Professor Kathryn Abel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.

Medpace

Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>

 
Industry Events

HPLC 2018

29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA

Are you interested in mass spectrometry, chromatography, or electrophoresis? Are you solving complex analytical problems? Are you looking for a conference with strong scientific content, a robust program, presentations by world renowned experts, lectures by young scientists, courses offering great training opportunities, tutorials, panel discussions, vendor technical workshops, best poster competition, and a major exposition showcasing new product launches and innovative products? Mark your calendar to attend HPLC 2018 Washington, DC, the largest, most recognized international conference in the world devoted to advances in separation technologies!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement